Research programme: focal adhesion protein tyrosine kinase inhibitors - undisclosed company

Drug Profile

Research programme: focal adhesion protein tyrosine kinase inhibitors - undisclosed company

Alternative Names: Protein kinase inhibitors - Poniard/Scripps Research Institute; Protein tyrosine kinase 2 inhibitors; PTK2 inhibitors

Latest Information Update: 25 Jan 2013

Price : $50

At a glance

  • Originator The Scripps Research Institute
  • Developer Unknown
  • Class Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 01 Jan 2013 No development reported - Preclinical for Cancer (unspecified route)
  • 18 Nov 2011 Preclinical trials in Cancer (unspecified route)
  • 18 Nov 2011 Focal adhesion kinase inhibitors and related technology licensed to an undisclosed company worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top